# Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

> **NCT07511972** · PHASE2 · WITHDRAWN · sponsor: **NGM Biopharmaceuticals, Inc**

## Conditions studied

- CRC

## Interventions

- **DRUG:** NGM707 plus pembrolizumab

## Key facts

- **NCT ID:** NCT07511972
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-11-14
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07511972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07511972, "Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07511972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*